References
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association; 2013. doi:10.1176/appi.books.9780890425596.
- Cunnington D, Junge MF, Fernando AT. Insomnia: prevalence, consequences and effective treatment. Med J Aust. 2013;199(8):S36–40. doi:10.5694/mja13.10718.
- Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Re s. 2017;26(6):675–700. doi:10.1111/jsr.12594.
- Olfson M, Wall M, Liu SM, Morin CM, Blanco C. Insomnia and Impaired Quality of Life in the United States. J Clin Psychiatry. 2018;79(5). doi:10.4088/JCP.17m12020.
- Nowicki Z, Grabowski K, Cubała W, et al. Prevalence of self-reported insomnia in general population of Poland. Psychiatr Pol. 2016;50(1):165–173. doi:10.12740/PP/58771.
- Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults. Journal of Clinical Sleep Medicine. 2008;04(05):487–504. doi:10.5664/jcsm.27286.
- Dopheide JA. Insomnia overview: epidemiology, pathophysiology, diagnosis and monitoring, and nonpharmacologic therapy. Am J Manag Care. 2020;26(4 Suppl):S76-S84. doi:10.37765/ ajmc.2020.42769.
- Gonçalves MT, Malafaia S, Moutinho Dos Santos J, Roth T, Marques DR. Epworth sleepiness scale: A meta-analytic study on the internal consistency. Sleep Med. 2023;109:261–269. doi:10.1016/j. sleep.2023.07.008.
- Morin CM, Belleville G, Bélanger L, Ivers H. The Insomnia Severity Index: Psychometric Indicators to Detect Insomnia Cases and Evaluate Treatment Response. Sleep. 2011;34(5):601–608. doi:10.1093/ sleep/34.5.601.
- Morin CM, Bélanger L, LeBlanc M, et al. The Natural History of Insomnia. Arch Intern Med. 2009;169(5):447. doi:10.1001/archinternmed.2008.610.
- Baranwal N, Yu PK, Siegel NS. Sleep physiology, pathophysiology, and sleep hygiene. Prog Cardiovasc Di s. 2023;77:59–69. doi:10.1016/j.pcad.2023.02.005.
- Claustrat B, Leston J. Melatonin: Physiological effects in humans. Neurochirurgie. 2015;61(2–3):77–84. doi:10.1016/j.neuchi.2015.03.002.
- Fuller PM, Gooley JJ, Saper CB. Neurobiology of the sleep-wake cycle: sleep architecture, circadian regulation, and regulatory feedback. J Biol Rhythm s. 2006;21(6):482–493. doi:10.1177/0748730406294627.
- Rosenberg R, Citrome L, Drake CL. Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies. Neuropsychiatr Dis Treat. 2021;17:2549–2566. doi:10.2147/NDT.S297504.
- LeBlanc M, Beaulieu-Bonneau S, Mérette C, Savard J, Ivers H, Morin CM. Psychological and health-related quality of life factors associated with insomnia in a population-based sample. J Psychosom Re s. 2007;63(2):157–166. doi:10.1016/j.jpsychores.2007.03.004.
- Roth T, Roehrs T, Pies R. Insomnia: Pathophysiology and implications for treatment. Sleep Med Rev. 2007;11(1):71–79. doi:10.1016/j.smrv.2006.06.002.
- Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med. 2007;3(5 Suppl):S7–10.
- Vozoris NT. The relationship between insomnia symptoms and hypertension using United States population-level data. J Hyperten s. 2013;31(4):663–671. doi:10.1097/HJH.0b013e32835ed5d0.
- Benca RM. Consequences of insomnia and its therapies. J Clin Psychiatry. 2001;62 Suppl 10:33–38.
- Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011;135(1–3):10–19. doi:10.1016/j. jad.2011.01.011.
- McCall WV, Blocker JN, D’Agostino R, et al. Insomnia severity is an indicator of suicidal ideation during a depression clinical trial. Sleep Med. 2010;11(9):822–827. doi:10.1016/j.sleep.2010.04.004.
- Metlaine A, Leger D, Choudat D. Socioeconomic impact of insomnia in working populations. Ind Health. 2005;43(1):11–19. doi:10.2486/indhealth.43.11.
- Katz DA, McHorney CA. The relationship between insomnia and health-related quality of life in patients with chronic illness. J Fam Pract. 2002;51(3):229–235.
- Chattu VK, Manzar MdD, Kumary S, Burman D, Spence DW, Pandi-Perumal SR. The Global Problem of Insufficient Sleep and Its Serious Public Health Implications. Healthcare. 2018;7(1):1. doi:10.3390/ healthcare7010001.
- Daley M, Morin CM, LeBlanc M, Grégoire JP, Savard J. The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers. Sleep. 2009;32(1):55–64.
- Riemann D, Espie CA, Altena E, et al. The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023. J Sleep Re s. 2023;32(6):e14035. doi:10.1111/jsr.14035.
- Sivertsen B, Omvik S, Pallesen S, et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA. 2006;295(24):2851–2858. doi:10.1001/jama.295.24.2851.
- Ong JC, Shapiro SL, Manber R. Combining mindfulness meditation with cognitive-behavior therapy for insomnia: a treatment-development study. Behav Ther. 2008;39(2):171–182. doi:10.1016/j. beth.2007.07.002.
- Lader M. Benzodiazepine harm: how can it be reduced? Br J Clin Pharmacol. 2014;77(2):295–301. doi:10.1111/j.1365–2125.2012.04418.x.
- Votaw VR, Geyer R, Rieselbach MM, McHugh RK. The epidemiology of benzodiazepine misuse: A systematic review. Drug Alcohol Depend. 2019;200:95–114. doi:10.1016/j.drugalcdep.2019.02.033.
- Wichniak A, Wierzbicka A, Jarema M. Treatment of insomnia – effect of trazodone and hypnotics on sleep. Psychiatr Pol. 2021;55(4):743–755. doi:10.12740/PP/125650.
- Everitt H, Baldwin DS, Stuart B, et al. Antidepressants for insomnia in adults. Cochrane Database Syst Rev. 2018;5(5):CD010753. doi:10.1002/14651858.CD010753.pub2.
- Siafis S, Tzachanis D, Samara M, Papazisis G. Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects. Curr Neuropharmacol. 2018;16(8):1210–1223. doi:10.2174/15 70159X15666170630163616.
- Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Re s. 2007;16(4):372–380. doi:10.1111/j.1365–2869.2007.00613.x.
- Morin CM, Jarrin DC, Ivers H, Mérette C, LeBlanc M, Savard J. Incidence, Persistence, and Remission Rates of Insomnia Over 5 Years. JAMA Netw Open. 2020;3(11):e2018782. doi:10.1001/ jamanetworkopen.2020.18782.
- Nutt D, Wilson S, Paterson L. Sleep disorders as core symptoms of depression. Dialogues Clin Neurosci. 2008;10(3):329–336. doi:10.31887/DCNS.2008.10.3/dnutt.
- Kunz D, Dauvilliers Y, Benes H, et al. Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder. CNS Drug s. 2023;37(1):93–106. doi:10.1007/s40263–022–00980–8.